Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
March 10, 2020
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
February 18, 2020
Assignees:
Beth Israel Deaconess Medical Center, Inc., Emory University
Inventors:
Keith A. Reimann, Rijian Wang, Christian P. Larsen
Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
January 28, 2020
Assignee:
Janssen Biotech, Inc.
Inventors:
Johan Fransson, Paul Kim, Michael Quigley, Andressa Smith, Alexey Teplyakov, Hong Zhou
Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
Type:
Grant
Filed:
January 31, 2014
Date of Patent:
January 14, 2020
Assignee:
Thomas Jefferson University
Inventors:
Mark L. Tykocinski, Matthew Charles Weber
Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Type:
Grant
Filed:
May 26, 2017
Date of Patent:
December 31, 2019
Assignee:
AbbVie Biotherapeutics Inc.
Inventors:
Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Type:
Grant
Filed:
June 28, 2016
Date of Patent:
November 19, 2019
Assignees:
Bristol-Myers Squibb Company, The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
Abstract: The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Abstract: Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).
Type:
Grant
Filed:
September 21, 2012
Date of Patent:
November 12, 2019
Assignees:
CSL BEHRING GMBH, THE GOVERNMENT OF THE UNITED STATES OF AMERICA
Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
Type:
Grant
Filed:
December 20, 2016
Date of Patent:
October 29, 2019
Assignee:
Bioverativ USA Inc.
Inventors:
Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Type:
Grant
Filed:
March 29, 2018
Date of Patent:
October 22, 2019
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
Type:
Grant
Filed:
December 20, 2016
Date of Patent:
October 22, 2019
Assignee:
Bioverativ USA Inc.
Inventors:
Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
Type:
Grant
Filed:
March 9, 2015
Date of Patent:
October 8, 2019
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
September 3, 2019
Assignee:
AbbVie Biotherapeutics Inc.
Inventors:
Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.